The purpose of this study is to assess how much of apremilast is found in the blood unchanged
when administered as an oral suspension compared to when it is administered as a tablet
formulation. The effect of food on apremilast oral suspension will also be evaluated. In
addition, information on the safety and tolerability of apremilast will be obtained.
CC-10004 (also known as apremilast or Otezla®) has been approved by the Food and Drug
Administration (FDA) for the treatment of active psoriatic arthritis (PsA) and moderate to
severe plaque psoriasis in adults. The liquid formulation of apremilast is an investigational
drug being developed by Celgene Corporation to treat plaque psoriasis in children. An
investigational drug is not approved by the U.S. Food and Drug Administration (FDA).